Science and Technology Production
Medicina - Effects of metformin and losartan on the release of vascular prostanoids in two models of dietary alteration in the rat
Congress
Authorship:
Lee HJ ; Cantú SM ; Donoso AS ; Alvarez Primo M ; CHOI, MARCELO ROBERTO ; Peredo H ; Puyó AMDate:
2018Publishing House and Editing Place:
Revista MedicinaSummary *
Fructose overload (F) and high-fat (HF) diet are experimental models that resemble human metabolic syndrome (MS). Mesenteric vascular bed (MVB) is formed by resistance vessels and a source of prostanoids (PR). Metformin (M) and losartan (L) are used for MS and high blood pressure (BP) treatment. We analyze M and L effects on PR release. Nine groups of male Sprague-Dawley rats were studied (9 weeks): Control (C): standard diet (SD) and tap water (W); fructose-overloaded (F): SD and F solution (10% w/v); HF diet (HF): 50% (w/w) bovine fat added to SD and W; C+M (CM): SD + 500 mg/Kg/day M in W; C+L (CL): SD + 30 mg/Kg/day L in W; F+M (FM): SD and M in F solution; F+L (FL): SD and L in F solution; HF+M (HFM): HF + M in W; HF+L (HFL): HF + L in W. Released PR were measured by HPLC (ng PR/mg tissue). HF increased vasoconstrictor prostaglandin (PG) F2α (HF: 155 ± 7 vs. C: 83 ± 3, p <0.01) and thromboxane (TX) B2 (HF: 119 ± 5 vs. C: 62± 2, p <0, 01) release; prevented by M and L, (HFM: 88±9 and HFL: 89±7 vs. HF, p<0.01; HFM: 59±7 and HFL: 71±3 vs. HF, p<0.01, respectively). F decreased vasodilator PG 6 -keto F1α (F: 62 ± 4 vs. C: 103 ± 3, p <0.01) and PGE2 (F: 48 ± 3 vs. C: 94 ± 3, p <0.01), prevented by L (FL: 112±10 vs. F, p<0.05 and FL: 96±10 vs. F, p<0.05 respectively). Meanwhile M only decreased PGF2α (FM: 55±4 vs. F, p<0.01) and TXB2 (FM: 45±10 vs. F, p<0.01). In conclusion, a possible mechanism by which M and L prevent BP increase in both models could be the prevention of the imbalance between vasodilator and vasoconstrictor PR release in MVB. Information provided by the agent in SIGEVAKey Words
HIPERTENSION ARTERIALPROSTANOIDESDIETA ALTA EN GRASALOSARTAN